Correlation between resistance of *Pseudomonas aeruginosa* to benzalkonium chloride and expression of efflux pump genes

Mohamed El-Sayed Osman¹, Hoda Hamed El-Hendawy¹, Said Mohamed Abd El-All², Ahmed Mohamed Hassan¹, Dina Ezzat Mahmoud⁴*

¹Professor of Microbiology, Department of Botany and Microbiology, Faculty of Science, Helwan University, Egypt.
²Professor of Microbiology, National Organization for Drug Control and Research (NODCAR), Cairo, Egypt.
³Researcher, Department of Microbiology, National Organization for Drug Control and Research (NODCAR), Cairo, Egypt.
⁴Researcher Assistant, Department of Microbiology, National Organization for Drug Control and Research (NODCAR), Cairo, Egypt.

**ARTICLE INFO**

Received on: 29/09/2018
Accepted on: 22/10/2018
Available online: 30/12/2018

**Key words:** *Pseudomonas aeruginosa*, benzalkonium chloride (BC), cross-resistance, efflux pump, efflux pump inhibitors, sertraline.

**ABSTRACT**

Study of cross-resistance to other antimicrobial agents and efflux pump (EP) resistance mechanism in benzalkonium chloride (BC) adapted *Pseudomonas aeruginosa* isolates. Minimum inhibitory concentration (MIC) of BC of 88 *P. aeruginosa* isolates that collected from clinical settings in Egypt and cross-resistance of BC-adapted isolates to other antimicrobial agents were determined by agar dilution method. EP regulatory genes (i.e., MexR, NfxB, MexT, and MexZ) were detected by PCR in BC adapted isolates, and then EP activity of isolates which have these four genes was determined by cartwheel method followed by sequencing for the isolate which showed the highest EP activity. Finally, the expression of EP genes (MexA, MexC, MexE, and MexX) was determined in the same isolate by real-time polymerase chain reaction (RT-PCR) in presence and absence of the most potent efflux pump inhibitor (EPI). Twenty isolates were BC-adapted with MIC 2,048 mg/l, showed cross-resistance to cetrimide and ciprofloxacin but not to other disinfectants used. The isolate no. 87 selected to be sequenced. Mutation founded in MexR (V126E) and MexZ (L138R) genes. By RT-PCR, sertraline (the most potent EPI used) decreased the expression of the EP genes to three-folds. These results demonstrate that EP was the major mechanism of resistance to BC.

**INTRODUCTION**

Disinfectants have a vital role in keeping acceptable health standards by significantly decreasing microbial loads and inactivating pathogens (Antonio *et al.*, 2017). Quaternary ammonium compounds (QACs) are the main biocide (antiseptics and disinfectants) used in various fields such as health care and agriculture as well as in industry (Ebrahimi *et al.*, 2016).

Benzalkonium chloride (BC) is the most important QACs used for surfaces disinfection in medical care applications because of their antibacterial activity (Antunes *et al.*, 2016) in addition to its important use as a preservative in aqueous formulations to prevent several infections (Nones *et al.*, 2017).

*Pseudomonas aeruginosa* is considered to be a frequent and severe cause of acute nosocomial infections, especially affecting intensive care unit (ICU) and immune-compromised patients (Cabot *et al.*, 2016). Previous studies suggested that exposure to subinhibitory concentrations of BC leads to co- and cross-resistance to other antimicrobial agents (Rakic-Martinez *et al.*, 2011).

*Pseudomonas aeruginosa* resists the lethal effects of BC by several mechanisms, such as increased efflux pump activity, mutations in GyrA and ParC genes that encode DNA gyrase and topoisomerase IV in addition to changes in the bacterial membrane (Ferreira *et al.*, 2011).

While there are at least 12 structural genes for the resistance-nodulation-division efflux systems have been identified in *P. aeruginosa* genome, four of them are clinically-important (MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM) (Lister *et al.*, 2009). Mex systems co-expression has been reported in *P. aeruginosa* clinical isolates where its variable effect on antibiotic susceptibility has been observed (Poonsuk and Chuanchuen, 2014).

*Corresponding Author*

Dina Ezzat Mahmoud, Researcher Assistant, National Organization for Drug Control and Research (NODCAR), Cairo, Egypt.

E-mail: Dina91286@yahoo.com

© 2018 M. El-Sayed Osman *et al*. This is an open access article distributed under the terms of the Creative Commons Attribution License -NonCommercial-ShareAlikeUnported License (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Phenotypic and genetic tests used to identify acquired resistance due to efflux pump overexpression in P. aeruginosa isolates. Over-expression of efflux pumps could increase the MICs of many antimicrobials. Different compounds have been known as efflux pump inhibitors (EPIs) due to its ability to broadly inhibit several known multidrug EPs in P. aeruginosa (Adabi et al., 2015). The purpose of this study was the cross-resistance determination of the BC-adapted P. aeruginosa with other antimicrobial agents. In addition to phenotypic and genotypic evaluation of the resistance caused by efflux pump activity.

MATERIALS AND METHODS

Bacterial isolates

Totally, 88 non-duplicated P. aeruginosa isolates were collected from clinical settings at four hospitals, Kasr El-Aini Hospital, Ain-Shams University Hospital, Chest Hospital, and Al Salam Hospital in Cairo, Egypt along the period of January–March 2015. Isolates those were Gram-negative with greenish-yellow colonies, fluorescent-yellow colonies, and blue color colonies on Cetrimide Agar, Pseudomonas Agar F, and Pseudomonas Agar P, respectively. Oxidase, catalase, and nitrate reductase positive isolates were identified as P. aeruginosa (Mahon et al., 2014). Pseudomonas aeruginosa wild-type strain (ATCC 15442) was purchased from Microbiologica USA.

Benzalkonium chloride

BC was purchased from Scharlabs S. L., Spain.

Minimum inhibitory concentration (MIC) of benzalkonium chloride

The MIC of benzalkonium chloride was carried out against the 88 P. aeruginosa isolates and P. aeruginosa strain (ATCC 15442) using agar dilution method due to precipitation of BC at high concentrations, following Clinical and Laboratory Standards (CLSI) (formerly NCCLS) in document M100-S14 (NCCLS, 2004; Kawamura-Sato et al., 2010). One microliter of each bacterial suspension contained 10^6 cfu ml^{-1} was inoculated on Mueller-Hinton agar (Oxoid) with different BC concentrations, then incubated at 37°C for 18 hours and the MIC was recorded. The BC adapted isolates were selected for further investigation.

Antibiotics susceptibility testing (disk diffusion method)

Antibiotic susceptibility pattern of BC-adapted isolates was determined by the single disk diffusion test (Kirby-Bauer method) (Bauer et al., 1966; CLSI, 2008). According to CLSI (2008), the following antibiotic discs (Oxoid) were used: Gentamicin—CN (10 µg), Pipercillin–tazobactam PIP/TAZ (100/10 µg), Ciprofloxacin—CIP (5 µg), Amikacin—AK (30 µg), Ceftazidime—CAZ (30 µg), Imipenem—IPM (10 µg), and Piperacillin—PRL (100 µg)

Determination of cross-resistance to other antimicrobials

The MIC of cetrimide (Hopkin & Williams, UK), iodine (El-Nile Company, Egypt), and ciprofloxacin (ADWIA, Egypt) was determined by the agar dilution method (Kawamura-Sato et al., 2010; NCCLS, 2004), but due to ethanol (Fisher Scientific, UK) vaporization, its MIC was determined by macro-dilution method (Mazzola et al., 2009).

Detection of efflux pump genes by PCR technique

PCR amplification of the efflux pump regulatory genes (MexR, NfxB, MexT, and MexZ) was performed using primers shown in Table 1 (Linares et al., 2005). The PCR mixture containing 100 ng of chromosomal DNA, 0.5 µM concentration of each primer, and Dream Taq™ Green PCR Master Mix (Thermo-Fisher Scientific, USA) was heated for 3 minutes at 94°C. This was followed by 32 cycles of 30 seconds at 94°C; 30 seconds at 53°C (NfxB), 55°C (MexT), 58°C (MexR), or 60°C (MexZ); and 60 seconds at 72°C, with final 10 minutes extension step at 72°C.

Phenotypic determination of efflux pumps activity

Ethidium bromide (EtBr)-agar cartwheel method (screening method)

Plates of Tryptic Soy Agar (TSA) containing EtBr concentrations (Sigma Aldrich) ranging from 0 to 5 mg/l were swabbed with bacterial cultures. Cartwheel pattern was made by dipping a swab into each culture and streaked them from the central circle to the margin of the plate.

EtBr-agar plates were incubated for 16–18 hours at 37°C. Each EtBr plate was examined under a UV light. The minimal concentration of EtBr which produced fluorescence of the swabbed culture was recorded for the wild-type strain and BC-adapted isolates. The higher the concentration of EtBr required for the appearance of fluorescence the greater the presumptive EP activity (Martins et al., 2013).

Sequencing of the efflux pump genes

PCR products of the selected isolate and P. aeruginosa ATCC 15442 strain were purified using the DNA purifying kit

Table 1. Primer sequences used in efflux pump regulatory genes detection.

<table>
<thead>
<tr>
<th>Efflux pumps</th>
<th>Gene</th>
<th>Product size (bp)</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>MexAB-OprM</td>
<td>mexR</td>
<td>637</td>
<td>Forward: GCCCATGGGCCCATATTGAG&lt;br&gt;Reverse: GGCATTCGCCGAGTAACCGG</td>
</tr>
<tr>
<td>MexCD-OprJ</td>
<td>nfxB</td>
<td>939</td>
<td>Forward: CG ATCCCTTCTATTGACAGC&lt;br&gt;Reverse: GCGAAGTGGCCAGATTCG</td>
</tr>
<tr>
<td>MexEF-OprN</td>
<td>mexT</td>
<td>997</td>
<td>Forward: CGGTTCGACGCTTATGCC&lt;br&gt;Reverse: CGATTTCGCCGTTGCCAGCG</td>
</tr>
<tr>
<td>MexXY-OprM</td>
<td>mexZ</td>
<td>781</td>
<td>Forward: AGCGGCGCGACATGGCATACGA&lt;br&gt;Reverse: CCGAGGACCGACGCAGCG</td>
</tr>
</tbody>
</table>
(Thermo Fischer, USA) following the manufacturer’s instruction. The samples were processed using DNA sequencing kit (Thermo Fischer, USA) and analyzed in an automatic DNA sequencer (Applied Biosystem—serial no. G: 43 A: 39 T: 30 C: 41) in order to analyze mutation in genes. The DNA sequences were aligned and homology searches were performed using BLAST program (www.ncbi.nlm.nih.gov/blast) and the translation to amino acids was performed using ExPASy translate https://web.expasy.org/translate/.

**Efflux pumps inhibitors (EPIs) (confirmatory method)**

**Determination of MIC of EPIs**

The MIC of EPIs (listed in Table 2) has been determined by microtiter method (Wiegand et al., 2008). A 100 µl of broth was added into the negative control well (column 12) and 50 µl into the positive control well (column 11). Fifty microliters of each EPIs dilution (twice the desired final conc.) was added into the respective well (columns 1–10) for each bacterial isolates. The bacterial suspension was adjusted to $1 \times 10^8$ 1 ml$^{-1}$ and diluted to 1:100. All wells except the negative control were inoculated with 50 µl of the bacterial inoculums with final inoculum concentration $5 \times 10^3$ cfu ml$^{-1}$.

**Determination of MIC of BC in combination with EPIs**

The antimicrobial efficacy of BC in combination with EPIs against BC-adapted *P. aeruginosa* was evaluated using the agar dilution method. The concentrations tested typically ranged from 2 to 3 concentration below the MIC of BC and EPIs. Organisms and agar dilution plates were prepared as for the MIC determination with exception of the addition of BC and EPIs plus an addition of agar medium to reach the 20 ml of the total (NCCLS, 2004). The fractional inhibitory concentration (FIC) index was calculated to evaluate the effect of the combinations (Satish et al., 2005).

**Genotypic determination of efflux pumps activity**

**Gene expression analysis of MexA, MexC, MexE, and MexX by real-time PCR**

RT–PCR was used to determine the expression of the genes encoding the four major *P. aeruginosa* efflux pumps MexA, MexC, MexE, and MexX of the selected isolate and *P. aeruginosa* wild-type strain ATCC 15442 (as a control).

Total RNA was extracted by the RNeasy Mini Kit (Qiagen, Germany) following its instructions and QIAGEN RNase-Free DNase Set (Qiagen, Germany) was used to remove the residual DNA. Finally, RNA was dissolved in 50 µl of RNase-free water. Synthesis of cDNA was performed by reverse transcription using QIAGEN OneStep RT-PCR Kit (Thermo Fisher). rpsL gene expression was measured as an internal control for confirmation that the amounts of RNA were equal in all of the RT-PCR. The amplification of the selected genes was performed with specific primers (listed in Table 3). The reaction mixtures were incubated at 50°C for 30 minutes and 5 minutes at 94°C. Followed by 40 cycles of 15 seconds at 94°C; 30 seconds at 57°C (for MexA), 55°C (for MexC and MexE), 60°C (for MexX and rpsL); and 1 minute at 72°C, with final 7 minutes elongation at 72°C (Linares et al., 2005).

**Analysis of the SYBR green RT-PCR results**

Stratagene MX3005P software was used to determine the amplification curves and Ct values. The Ct of each sample was compared with that of the control group according to the “ΔΔCt” method to estimate the variation of gene expression on the RNA of the different samples (Yuan et al., 2006).

**RESULTS AND DISCUSSION**

Antibiotic resistance in bacterial pathogens has increased worldwide in the last decade leading to failures in the treatment of infectious diseases in human and animals (Gnanadhas et al., 2013).

**Table 2. Efflux pumps inhibitors used.**

<table>
<thead>
<tr>
<th>Efflux pumps inhibitor</th>
<th>Solvent</th>
<th>Manufacturer company</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCCP</td>
<td>Dimethylsulfoxide (DMSO)</td>
<td>Sigma Aldrich (USA)</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>HCl</td>
<td>EL Nasr Co.</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>H$_2$O</td>
<td>MISR Co. Egypt</td>
</tr>
<tr>
<td>Sertraline</td>
<td>DMSO</td>
<td>Global Pharmaceutical Industries, Egypt</td>
</tr>
</tbody>
</table>

**Table 3. Primers used in RT-PCR.**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Product size (bp)</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>mexA</td>
<td>332</td>
<td>Forward: CCTGCTGGTGCGCGGATTTCGG</td>
</tr>
<tr>
<td></td>
<td>Reverse: CCACGAGCTTGTAGCGCTGG</td>
<td></td>
</tr>
<tr>
<td>mexC</td>
<td>390</td>
<td>Forward: TTGGCTATGGCCATCGCTTGA</td>
</tr>
<tr>
<td></td>
<td>Reverse: ATGCAAGTCTGCTGGCTGA</td>
<td></td>
</tr>
<tr>
<td>mexE</td>
<td>260</td>
<td>Forward: ATCCACTTCTTCTTGGCCTT</td>
</tr>
<tr>
<td></td>
<td>Reverse: GGTCGCCTTTCTTCAACAGT</td>
<td></td>
</tr>
<tr>
<td>mexX</td>
<td>812</td>
<td>Forward: GGATGCGGATTGCGGAACA</td>
</tr>
<tr>
<td></td>
<td>Reverse: TGTCGCGGCTATTTGCCTGG</td>
<td></td>
</tr>
<tr>
<td>RPSL*</td>
<td>231</td>
<td>Forward: GCCACTTACACACAGCCTG</td>
</tr>
<tr>
<td></td>
<td>Reverse: GCCTGCTCTTGCGAGGTG</td>
<td></td>
</tr>
</tbody>
</table>

*The ribosomal rpsL gene was used as a housekeeping reference gene.*
Nosocomial infection is a worldwide problem and reported in 7%–8% of in-patients. *Pseudomonas aeruginosa* is responsible for 6%–25% of nosocomial infections. Treatment of infections caused by *P. aeruginosa* is very complicated because of their remarkable virulence characteristics and frequent antibiotic resistance (Yuruken et al., 2016).

Benzalkonium chloride (BC) is a QAC which have broad-spectrum antimicrobial activity (Ebrahimi et al., 2016; McCay et al., 2010). Low and higher level of adaptation to the BC has been observed in *P. aeruginosa* strains (Langsrud et al., 2003). Adaptation to BC in *P. aeruginosa* is mediated primarily by the efflux pumps activity, most notably the Mex systems (Lomovskaya et al., 1999). Vijaya et al. (2016) reported that about 22% of multidrug-resistant *P. aeruginosa* isolates showed insusceptibility to BC.

**Determination of minimal inhibitory concentration (MIC) of Benzalkonium Chloride (BC) against Pseudomonas aeruginosa isolates**

The MIC of the wild-type strain and *P. aeruginosa* isolates were shown in Table 4, which indicated that 20 isolates were 2,048 mg/l, 55 isolates were 512 mg/l, and 13 isolates, as well as wild-type strain was 256 mg/l. The 20 BC-adapted isolates were selected for the further testing.

Lambert and Pearson (2000) reported that the MIC of BC against *P. aeruginosa* isolates was 4,844, 1,462, 346, and 83.7 mg/l. Also, Walsh et al. (2003) found the MIC of BC against *P. aeruginosa* isolates was 500 mg/l.

**Sources of the 20 BC-adapted isolate**

The 20 BC-adapted isolates were collected from ICU, sputum, pus, urine, and wounds (Fig. 1).

**Antibiotics susceptibility screening by Disk diffusion method**

The antibiotics susceptibility of the 20 BC-adapted isolates against the selected antibiotics is shown in Figure 2, which indicates that all isolates were resistant to at least six antibiotics (multidrug resistant).

**Determination of cross-resistance to the other antimicrobial agents**

The MIC values of the selected 20 BC-adapted isolates and the wild-type strain ATCC 15442 were compared with cetrimide (QAC), ethanol (Alcohol), iodine (halogens), and ciprofloxacin (quinolones) for determination of cross-resistance to the other antimicrobial agents. The obtained results showed that the 20 BC-adapted isolates were also adapted to cetrimide with MIC 7,000 mg/l and ciprofloxacin with MIC was 64 or 128 mg/l, but not adapted to ethanol and iodine. As reported by Buffet-Bataillon et al. (2016), it was found that adaptation to BC leads to cross-resistance with fluoroquinolones.

**Detection of efflux pump genes (MexR, NfxB, MexT, and MexZ) by PCR technique**

The amplification products of MexR, NfxB, MexT, and MexZ genes were identified by agarose gel electrophoresis with ethidium bromide staining. The amplified products were 637-bp fragment for MexR gene, 939-bp fragment for NfxB, 997-bp fragment for MexT gene, and 781-bp fragment for MexZ gene. MexR gene was detected in 16 isolates, NfxB gene in 18 isolates, MexT gene in 10 isolates, and MexZ gene in 17 isolates (Fig. 3).

The four genes were found collectively in nine isolates (isolates no. 7, 15, 28, 37, 51, 52, 86, 87, and 154), these nine isolates were selected for the further investigation.

**Evaluation of the efflux pump activity by Ethidium bromide (EtBr) cartwheel method**

The presumptive identification of the highest EP activity in the nine isolates and the wild-type strain ATCC 15442 was carried out by using the EtBr-agar Cartwheel method. Isolates express efflux pumps by variable levels as shown in Figure 4. The ATCC strain was found to fluoresce at conc. 0.5 mg/l of EtBr, which means it has no efflux pump activity (negative control).

The minimum concentration at which the adapted isolates showed fluorescence was 1mg/l for isolates no. 15, 51, and 154, while 2.5 mg/l for isolates no. 28 and 37, but isolate no. 86 was 4.5 mg/l, isolates no. 7 and 52 were 5 mg/l, however, the isolate no. 87 was more than 5 mg/l. These results were agreed

---

**Table 4. MIC values of BC.**

<table>
<thead>
<tr>
<th>No. of isolates</th>
<th>MIC value (mg/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild-type strain</td>
<td>256</td>
</tr>
<tr>
<td>13</td>
<td>256</td>
</tr>
<tr>
<td>55</td>
<td>512</td>
</tr>
<tr>
<td>20</td>
<td>2,048</td>
</tr>
</tbody>
</table>
with El-Naggar et al. (2011), who reported that EtBr was effluxed in *P. aeruginosa*.

The previous results revealed that isolate no. 87 has a high efflux pump activity.

**Sequencing**

To identify mutations, sequences of the selected isolate no. 87 and wild-type strain ATCC 15442 were compared with *P. aeruginosa* PAO1 (Pseudomonas Genome Database, [http://www.pseudomonas.com](http://www.pseudomonas.com)). Figures 5–8 showed the amino acids alignment of efflux pump regulatory genes MexR, NfxB, MexT, and MexZ of wild-type strain PAO1, wild-type strain ATCC 15442, and isolate no. 87, respectively.

As shown in Figures 5–8, in the MexR regulatory gene, a novel mutation in codon number 126 was correlated to resistance to fluoroquinolone, which is substitution of amino acid Valine (V) to Glutamic acid (E), which was reported in previous investigations (Nguyen et al., 2018; Vaez et al., 2018). Results of several independent studies revealed different mutations, for example, Suman et al. (2006) reported 24 silent and four missense mutations in 14 clinical isolates of *P. aeruginosa*, and Savov et al. (2014) found another mutation in codon 44 in one strain, substitution of amino acid lysine to methionine.

No mutations were detected in NfxB in this study, Esquisabel et al. (2011) found several different amino acid substitutions, while the amino acid substitutions of Asparagine (N) to Glycine (G) in codon 68 and Arginine (R) to Histidine (H) in codon 33 were previously reported in clinical strains of *P. aeruginosa* (Livermore, 2002; Suman et al., 2006).

In MexT, two substitutions were found, Proline (P) to Alanine (A) in codon 81 and Phenylalanine (F) to Isoleucine (I) in codon 172. These mutations were also observed in wild-type strain ATCC 15442 so they considered as a non-significant mutation.

In MexZ, three substitutions were found. One substitution was Leucine (L) to Arginine (R) in codon 138. In addition to two conservative substitutions producing amino acids with similar physiochemical properties [Methionine (M) to Valine (V) in codon 1 and Aspartic acid (D) to Glutamic acid (E) in codon 155]. These
Figure 4. Fluorescence of the isolates on agar plates containing increasing concentrations of EtBr. Cultures were swabbed in TSA plates containing increasing concentrations of EtBr. Following overnight incubation at 37°C for 16 hours, fluorescence was detected under UV light. No. 1: ATCC 15442, from 2 to 10 refer to isolates no. 7, 15, 28, 37, 51, 52, 86, 87, and 154, respectively.

Figure 5. Alignment of amino acid sequences of the MexR gene.

Figure 6. Alignment of amino acid sequences of the NfxB gene.
results were as reported by Nemat-Gorgani (2009). Esquisabel et al. (2011) observed the same substitution, but in another codon (Leu-162-Arg).

**Efflux pumps inhibitors (EPIs) (confirmatory method)**

The MIC values of carbonyl cyanide m-chlorophenylhydrazone (CCCP) was 128 mg/l and MIC value of sertraline was 1,000 mg/l for both isolates no. 87 and the wild-type strain ATCC 15442. But trimethoprim and epinephrine have no antimicrobial activity.

Efflux pump activity of isolate no. 87 was evaluated in the absence and presence of an efflux pump inhibitors (EPI) used. According to the obtained results, the insusceptibility of the isolate 87 to BC decreased upon the combination of BC with the sertraline (2,048–256 mg/l BC). Sertraline had the most potent antimicrobial activity among the four EPIs used. While CCCP, TMP, and EP have no effect.

The obtained results revealed that efflux pumps in isolate 87 play an important role in adaptation development to BC.

Data presented in Table 5 revealed that the FIC index values stated a partial synergistic antimicrobial activity of BC-Ser against all tested bacterial isolates (FIC > 0.5 but < 1).

Bohnert et al. (2011) reported that resistance of the isolates to BC decreased in the presence of the EPI. The mutant also showed a 94-fold decrease in sensitivity to ciprofloxacin (McCay et al., 2010).

**Real-time PCR**

Changes in expression of the MexA, MexC, MexE, and MexX genes of BC-adapted isolate no. 87 were measured in the absence and presence of a combination of BC + Ser. (at sub-inhibitory conc.); expression was compared to that of wild-type strain ATCC 15442 as shown in Table 6.

For untreated BC-adapted isolate no. 87, MexA gene was expressed at a 9.189-fold, MexC 8.5-fold, MexE 5.5-fold, and MexX 4-fold higher than the control sample. These results are in agreement with previous studies which reported that 4- to 10-fold increase in the activity of a mexA (Dumas et al., 2005; Gomaa et al., 2016; Pasca et al., 2012; Srikumar et al., 2000).

In another study by Wolter et al. (2009), it was documented that the expression of mexA gene in PA431 was two-fold higher than PA01, while genes mexC and mexE showed higher expression by about 340- to 375-fold, respectively, in PA30 than in PA01, and increased three- to four-fold in strain PA431. In another hand, of mexX gene expression in PA431 was higher than PA01 by 50-fold and lower in PA30 by two-fold.

McCay et al. (2010) observed that the expression of both mexA and mexC was increased in the BC-adapted isolate. Expression of mexE and mexX in BC-adapted isolate was half that of 10421 in absence of BC, although expression of mexX was increased in BC-adapted isolate than 10421 in presence of BC.

Decreased expression was noticed by the addition of a combination of BC + SER to the growth medium (256 mg/l BC + 700 mg/l SER); the expression of MexA, MexC, MexE, and MexX was decreased to 3.9-, 3-, 1.9-, and 1.4-fold, respectively. These results
indicated that BC-adapted isolates overexpressed the four efflux pump genes; and by treatment with sertraline (EPI), the expression of these genes was down-regulated to quarter; so we investigated that the efflux pump was the mainly resistant mechanism to the BC.

CONCLUSION

In conclusion, the indiscriminate use of BC in various fields and their accumulation represents a potential risk for selective pressure towards the selection of adapted bacteria, which could be cross-resistant to other disinfectants and antibiotics.

Although, in the present study, efflux pump overexpression seemed to be the main resistance mechanism of P. aeruginosa adaptation to BC; other mechanisms of resistance should be studied to combat this phenomenon.

Our approach in this study was to obtain a final product contained BC plus sertraline (efflux pump inhibitor) which can be used pharmaceutically to restore disinfectant activity against BC-adapted P. aeruginosa and minimize further developments of resistant strains.

REFERENCES


Wiegand I, Hilpert K, Hancock REW. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc, 2008; 3:163–75.

Wolter DJ, Black JA, Lister PD, Hanson ND. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype. J Antimicrob Chemother, 2009; 64(2):294–300.


How to cite this article: Osman ME-S, El-Hendawy HH, Abd El-All SM, Hassan AM, Mahmoud DE. Correlation between resistance of Pseudomonas aeruginosa to benzalkonium chloride and expression of efflux pump genes. J Appl Pharm Sci, 2018; 8(12): 044–052.